Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Malwine Barz"'
Autor:
Michela Carlet, Karin Schmelz, Jenny Vergalli, Tobias Herold, Daniela Senft, Vindi Jurinovic, Thomas Hoffmann, Jutta Proba, Nina Weichert, Christian Junghanß, Mareike Roth, Georg Eschenburg, Malwine Barz, Günter Henze, Cornelia Eckert, Angelika Eggert, Johannes Zuber, Patrick Hundsdoerfer, Irmela Jeremias
Publikováno v:
EMBO Molecular Medicine, Vol 15, Iss 1, Pp n/a-n/a (2023)
Abstract Acute lymphoblastic leukemia (ALL) represents the most frequent malignancy in children, and relapse/refractory (r/r) disease is difficult to treat, both in children and adults. In search for novel treatment options against r/r ALL, we studie
Externí odkaz:
https://doaj.org/article/b9528d06f61749f38311ce38d1fa6f9a
Autor:
Thomas Beder, Björn-Thore Hansen, Alina M. Hartmann, Johannes Zimmermann, Eric Amelunxen, Nadine Wolgast, Wencke Walter, Marketa Zaliova, Željko Antić, Philippe Chouvarine, Lorenz Bartsch, Malwine Barz, Miriam Bultmann, Johanna Horns, Sonja Bendig, Jan Kässens, Christoph Kaleta, Gunnar Cario, Martin Schrappe, Martin Neumann, Nicola Gökbuget, Anke Katharina Bergmann, Jan Trka, Claudia Haferlach, Monika Brüggemann, Claudia D. Baldus, Lorenz Bastian
Current classifications (WHO-HAEM5 / ICC) define up to 26 molecular B-cell precursor acute lymphoblastic leukemia (BCP-ALL) disease subtypes, which are defined by genomic driver aberrations and corresponding gene expression signatures. Identification
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c352f050053db7a1641511221b3ef54
https://doi.org/10.1101/2023.02.01.526553
https://doi.org/10.1101/2023.02.01.526553
Autor:
Michela Carlet, Karin Schmelz, Jenny Vergalli, Tobias Herold, Daniela Senft, Vindi Jurinovic, Thomas Hoffmann, Jutta Proba, Nina Weichert, Christian Junghanß, Mareike Roth, Georg Eschenburg, Malwine Barz, Günter Henze, Cornelia Eckert, Angelika Eggert, Johannes Zuber, Patrick Hundsdoerfer, Irmela Jeremias
Publikováno v:
EMBO Mol. Med.:e14557 (2022)
Acute lymphoblastic leukemia (ALL) represents the most frequent malignancy in children, and relapse/refractory (r/r) disease is difficult to treat, both in children and adults. In search for novel treatment options against r/r ALL, we studied inhibit